- Home
- PTIX vs SCNI Comparison
PTIX vs SCNI Comparison
Compare PTIX & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTIX
- SCNI
- Stock Information
- Founded
- PTIX 1994
- SCNI 2003
- Country
- PTIX United States
- SCNI Israel
- Employees
- PTIX N/A
- SCNI N/A
- Industry
- PTIX Biotechnology: Pharmaceutical Preparations
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PTIX Health Care
- SCNI Health Care
- Exchange
- PTIX Nasdaq
- SCNI Nasdaq
- Market Cap
- PTIX 1.9M
- SCNI 1.9M
- IPO Year
- PTIX 2016
- SCNI N/A
- Fundamental
- Price
- PTIX $3.03
- SCNI $2.91
- Analyst Decision
- PTIX
- SCNI
- Analyst Count
- PTIX 0
- SCNI 0
- Target Price
- PTIX N/A
- SCNI N/A
- AVG Volume (30 Days)
- PTIX 259.3K
- SCNI 15.6K
- Earning Date
- PTIX 05-27-2025
- SCNI 05-07-2025
- Dividend Yield
- PTIX N/A
- SCNI N/A
- EPS Growth
- PTIX N/A
- SCNI N/A
- EPS
- PTIX N/A
- SCNI N/A
- Revenue
- PTIX N/A
- SCNI $658,000.00
- Revenue This Year
- PTIX N/A
- SCNI N/A
- Revenue Next Year
- PTIX N/A
- SCNI N/A
- P/E Ratio
- PTIX N/A
- SCNI N/A
- Revenue Growth
- PTIX N/A
- SCNI N/A
- 52 Week Low
- PTIX $2.51
- SCNI $1.90
- 52 Week High
- PTIX $26.18
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- PTIX 45.51
- SCNI 60.01
- Support Level
- PTIX $2.82
- SCNI $2.66
- Resistance Level
- PTIX $3.68
- SCNI $2.96
- Average True Range (ATR)
- PTIX 0.54
- SCNI 0.18
- MACD
- PTIX 0.03
- SCNI 0.04
- Stochastic Oscillator
- PTIX 37.16
- SCNI 93.15
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.